This observational study set out to quantify how common antibodies to the adeno-associated virus (AAV) types AAV5, AAV6, and AAV8 are (seroprevalence) in people with hemophilia A, and how often such antibodies develop (seroconversion) over varying follow-up intervals. The only procedure is blood sample collection; no treatment is given. It enrolled people aged 18 or over with a diagnosis of hemophilia A who were not taking part in another interventional study and had not previously received AAV vector gene therapy.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Subjects diagnosed with Hemophilia A * Subjects aged 18years or over at time of entry Exclusion Criteria: * Currently participating in an interventional study of any investigational product, device or procedure. * Subjects who have been previously treated with AAV vector gene therapy